-

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE THERAPEUTICS, INC. (UNCY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On June 30, 2026, Unicycive disclosed that the FDA had issued a second Complete Response Letter (“CRL”) regarding the Company’s resubmitted New Drug Application for its kidney disease therapy, oxylanthanum, identifying the “same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025.”

On this news, Unicycive’s stock price fell $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Unicycive securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, Pennsylvania 19020
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com 

Law Offices of Howard G. Smith

NASDAQ:UNCY

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com 

More News From Law Offices of Howard G. Smith

Deadline Alert: Portillo's Inc. Stockholders Face January 11, 2027 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--Portillo's Inc. ("Portillo's" or the "Company") (NASDAQ: PTLO) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by January 11, 2027. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from September 19, 2023 through May 4, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Wassel v. Portillo's Inc. et...

Deadline Alert: Nuscale Power Corporation Stockholders Face January 11, 2027 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--Nuscale Power Corporation ("Nuscale" or the "Company") (NYSE: SMR) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by January 11, 2027. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 27, 2026 through September 10, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Chiu-Yueh Chang v....

Securities Fraud Class Action Lawsuit Pending Against Fervo Energy Company: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

BENSALEM, Pa.--(BUSINESS WIRE)--Fervo Energy Company ("Fervo" or the "Company") (NASDAQ: FRVO) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 13, 2026 initial public offering (“IPO” or the “Offering”). Plaintiff pursues claims under Section 1...
Back to Newsroom